Two more medicines subject to export ban
Two more medicines have been added to the list of medicines that cannot be parallel exported from the UK. The export ban on colestyramine sachets and fluticasone propionate nasules came into effect on December 5.
Since it was first published on October 4 the list of medicines subject to an export ban has grown to 35 products. The Department of Health and Social Care says the list has been created to ensure that medicines in short supply remain available to patients in the UK. “Sometimes the parallel export of a medicine can lead to or exacerbate supply shortages in the exporting country,” it says.
Parallel export is the practice of buying medicines already placed on the market in the UK in order to sell them in another country in the European Economic Area (EEA) where they are repackaged and relabelled in accordance with the requirements of the importing country. Anyone holding a UK wholesale dealer licence can parallel export a medicine but in practice parallel export is only undertaken by a small group of licence holders.
Record my learning outcomes
Inspiring stories related to health, fitness and the pursuit of wellbeing
More like this
Poorest women’s life expectancy falls in England’s ‘lost decade’
Women living in England’s poorest neighbourhoods have seen a decline in life expectancy since 2011.
2 Min Article
Royal Family hails pharmacy teams in Covid-19 fight
The Royal Family last night paid tribute to pharmacists and their teams in the fight against coronavirus.
2 Min Article
Relief from the nasal symptoms of allergy
With NHS England advising that OTC products should no longer be prescribed to treat mild-to-moderate hayfever, pharmacy’s role in supporting sufferers is more important than ever. This module includes self-care advice and product recommendations to aid customer conversations.
15 Min Module